Abstract
AbstractClinical trials with glaucoma have increased significantly over the last 30 years. The three main areas of clinical trials are in diagnostic tools, medical treatments, and new surgical strategies. While medical treatments have been the most common clinical trials, the number of clinical trials in surgery is now leading. In medical care, most new goals are new IOP‐lowering strategies, whereas clinical trials of neuroprotection and vascular modalities are still sparse. In addition to traditional medicine, dietary supplements and growth factors are also assessed for a potential anti‐glaucomatous effect. Within medical targets, the success rates for Phases II and III are below the reported success rate for all diseases and ophthalmology in general. The reasons for the low success rates can be explained, among other things, by the need for a stricter phenotyping of patients. Here, an overview of trends in clinical trials will be given and a future perspective will be discussed.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
